Recursion Pharmaceuticals, Inc. RXRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $753.92M+25.0% | $603.02M+50.2% | $401.43M-28.2% | $559.11M+89.3% | ||
| $4.59M+50.9% | $3.05M-5.8% | $3.23M+152% | $1.28M-17.5% | ||
| $11.74M-60.3% | $29.6M-26.5% | $40.25M+154% | $15.87M+111% | ||
| —— | —— | —— | —— | ||
| $812.85M+13.8% | $714.27M+63.0% | $438.14M-23.1% | $569.81M+6.6% | ||
| $103.93M-26.3% | $141.06M+63.1% | $86.51M-1.9% | $88.19M+36.3% | ||
| $75.78M+185% | $26.63M-40.6% | $44.87M+49.0% | $30.12M+60.7% | ||
| $45.34M-31.2% | $65.88M+95.7% | $33.66M+1.2% | $33.26M+1.1% | ||
| $162.16M+8.9% | $148.87M+186% | $52.06M+6,399% | $801K0.0% | ||
| $309.9M-7.7% | $335.86M+822% | $36.44M+2,690% | $1.31M-5.7% | ||
| $23.26M+40.3% | $16.58M+1,138% | $1.34M— | $0— | ||
| $12.75M+44.5% | $8.83M+3,281% | $261K— | $0-100% | ||
| $1.47B+1.8% | $1.45B+122% | $653.7M-6.8% | $701.29M+14.9% | ||
| $76.45M+133% | $32.75M+125% | $14.55M-8.0% | $15.81M+2.3% | ||
| $31.77M-61.2% | $81.87M+75.6% | $46.64M+41.7% | $32.9M+1.8% | ||
| $37.61M-39.1% | $61.77M+69.6% | $36.43M-35.8% | $56.73M+467% | ||
| $9.09M+7.9% | $8.43M+20,449% | $41K— | —— | ||
| $12.66M-8.2% | $13.8M+126% | $6.12M+2.8% | $5.95M— | ||
| $114.01M-4.0% | $118.77M+132% | $51.24M-27.1% | $70.26M+954% | ||
| $147.71M-21.2% | $187.47M+101% | $93.17M-7.1% | $100.27M+115% | ||
| $9.56M-49.7% | $19.02M+1,628% | $1.1M+105% | $536K-15.3% | ||
| $46.65M-30.6% | $67.25M+54.9% | $43.41M-2.3% | $44.42M— | ||
| $18.34M-31.2% | $26.65M— | —— | —— | ||
| $9.37M-48.9% | $18.34M— | $0— | —— | ||
| $2.08M-56.0% | $4.73M— | $0— | —— | ||
| $343.27M-17.0% | $413.82M+117% | $190.26M-11.7% | $215.48M+220% | ||
| 2B+49,999,900% | 4K+100% | 2K0.0% | 2K0.0% | ||
| $3.17B+28.2% | $2.47B+72.9% | $1.43B+27.2% | $1.13B+19.3% | ||
| -$2.08B-45.0% | -$1.43B-47.9% | -$967.62M-51.3% | -$639.56M-59.9% | ||
| $36.72M+581% | -$7.64M— | $0— | $0+100% | ||
| $1.13B+9.3% | $1.03B+123% | $463.44M-4.6% | $485.81M-10.5% | ||
| $1.47B+1.8% | $1.45B+122% | $653.7M-6.8% | $701.29M+14.9% | ||
| $28.57M-25.0% | $38.11M-5.3% | $40.25M+154% | $15.87M+111% | ||
| $24.65M-49.9% | $49.17M+1,489% | $3.09M+12.4% | $2.75M-69.6% | ||
| $24.65M-49.9% | $49.17M+1,489% | $3.09M+12.4% | $2.75M-69.6% | ||
| $12.75M+44.5% | $8.83M+3,281% | $261K— | $0-100% | ||
| $138.02M+7.2% | $128.78M+12,960% | $986K+9.1% | $904K0.0% | ||
| $138.02M+7.2% | $128.78M+12,960% | $986K+9.1% | $904K0.0% | ||
| $138.02M+7.2% | $128.78M+12,960% | $986K+9.1% | $904K0.0% | ||
| $138.02M+7.2% | $128.78M+12,960% | $986K+9.1% | $904K0.0% | ||
| $385.68M+6.4% | $362.49M+698% | $45.41M+2,047% | $2.12M+16.5% | ||
| $45.34M-31.2% | $65.88M+95.7% | $33.66M+1.2% | $33.26M+1.1% | ||
| $957K-50.5% | $1.93M— | $0— | —— | ||
| $309.9M-7.7% | $335.86M+822% | $36.44M+2,690% | $1.31M-5.7% | ||
| $45.34M-31.2% | $65.88M+95.7% | $33.66M+1.2% | $33.26M+1.1% | ||
| $12.75M+44.5% | $8.83M+3,281% | $261K— | $0-100% | ||
| $45.34M-31.2% | $65.88M+95.7% | $33.66M+1.2% | $33.26M+1.1% | ||
| $12.75M+44.5% | $8.83M+3,281% | $261K— | $0-100% | ||
| $0— | $0— | $0— | $0— | ||
| $31.77M-37.5% | $50.85M+122% | $22.89M+12.0% | $20.43M+74.1% | ||
| $114.01M-4.0% | $118.77M+132% | $51.24M-27.1% | $70.26M+954% | ||
| $70.23M-14.2% | $81.87M+75.6% | $46.64M+41.7% | $32.9M+1.8% | ||
| $70.23M-14.2% | $81.87M+75.6% | $46.64M+41.7% | $32.9M+1.8% | ||
| $31.77M-37.5% | $50.85M+122% | $22.89M+12.0% | $20.43M+74.1% | ||
| $9.09M+7.9% | $8.43M+20,449% | $41K— | —— | ||
| $1.23M+56.5% | $787K-50.3% | $1.58M— | —— | ||
| $114.01M-4.0% | $118.77M+132% | $51.24M-27.1% | $70.26M+954% | ||
| $9.56M-49.7% | $19.02M+1,628% | $1.1M— | —— | ||
| $114.01M-4.0% | $118.77M+132% | $51.24M-27.1% | $70.26M+954% | ||
| $96.3M-28.7% | $135.14M+167% | $50.67M-0.5% | $50.91M+5.1% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 528.2M+33.1% | 396.8M+69.4% | 234.3M+22.6% | 191M+12.2% | ||
| $5K+25.0% | $4K+100% | $2K0.0% | $2K0.0% | ||
| $8.28M— | —— | —— | —— | ||
| $2.69M-53.7% | $5.81M-4.4% | $6.08M+80.2% | $3.37M-28.0% | ||
| $4.58M+48.0% | $3.1M+20.4% | $2.57M-19.5% | $3.19M+51.0% | ||
| $3M0.0% | $3M— | —— | —— | ||
| $1.23M+56.5% | $787K-50.3% | $1.58M— | —— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | ||
| $2B0.0% | $2B0.0% | $2B0.0% | $2B0.0% | ||
| $528.18M+33.1% | $396.8M+69.4% | $234.27M+22.6% | $191.02M+12.2% | ||
| $528.18M+33.1% | $396.8M+69.4% | $234.27M+22.6% | $191.02M+12.2% | ||
| $23.26M+40.3% | $16.58M+1,138% | $1.34M— | $0— | ||
| $20.21M-23.1% | $26.27M— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $75.78M+185% | $26.63M+197% | $8.97M+1,009% | $809K+88.1% | ||
| $138.02M+7.2% | $128.78M+12,960% | $986K+9.1% | $904K0.0% | ||
| $385.68M+6.4% | $362.49M+698% | $45.41M+2,047% | $2.12M+16.5% | ||
| $9.56M-49.7% | $19.02M+1,628% | $1.1M— | —— | ||
| $9.09M+7.9% | $8.43M+20,449% | $41K— | —— | ||
| $0— | $0— | $0— | $0— | ||
| $703K-55.8% | $1.59M-34.6% | $2.43M+19.9% | $2.03M— | ||
| —— | —— | —— | —— | ||
| $17.97M+7.4% | $16.74M+93.5% | $8.65M+123% | $3.88M-47.2% | ||
| $11.74M-60.3% | $29.6M— | —— | —— | ||
| $10.63M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s total assets?
- Recursion Pharmaceuticals, Inc. (RXRX) holds $1.3B in total assets, up 2.6% year over year.
- How much debt does Recursion Pharmaceuticals, Inc. have?
- Recursion Pharmaceuticals, Inc. carries $88.6M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Recursion Pharmaceuticals, Inc. have?
- Recursion Pharmaceuticals, Inc. holds $665.2M in cash and equivalents.
- Can Recursion Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Recursion Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
